These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 25089529)

  • 1. Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study.
    Xing M; Prajapati HJ; Dhanasekaran R; Lawson DH; Kokabi N; Eaton BR; Kim HS
    Am J Clin Oncol; 2017 Feb; 40(1):27-34. PubMed ID: 25089529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic yttrium-90 radioembolization for metastatic melanoma: a single-center experience.
    Memon K; Kuzel TM; Vouche M; Atassi R; Lewandowski RJ; Salem R
    Melanoma Res; 2014 Jun; 24(3):244-51. PubMed ID: 24638152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yttrium-90 Microsphere Brachytherapy for Liver Metastases From Uveal Melanoma: Clinical Outcomes and the Predictive Value of Fluorodeoxyglucose Positron Emission Tomography.
    Eldredge-Hindy H; Ohri N; Anne PR; Eschelman D; Gonsalves C; Intenzo C; Bar-Ad V; Dicker A; Doyle L; Li J; Sato T
    Am J Clin Oncol; 2016 Apr; 39(2):189-95. PubMed ID: 24441583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients.
    Bester L; Meteling B; Pocock N; Pavlakis N; Chua TC; Saxena A; Morris DL
    J Vasc Interv Radiol; 2012 Jan; 23(1):96-105. PubMed ID: 22079516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization.
    Levey AO; Elsayed M; Lawson DH; Ermentrout RM; Kudchadkar RR; Bercu ZL; Yushak ML; Newsome J; Kokabi N
    Cardiovasc Intervent Radiol; 2020 Feb; 43(2):254-263. PubMed ID: 31686137
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Kurilova I; Beets-Tan RGH; Ulaner GA; Boas FE; Petre EN; Yarmohammadi H; Ziv E; Deipolyi AR; Brody LA; Gonen M; Sofocleous CT
    Cardiovasc Intervent Radiol; 2018 Sep; 41(9):1419-1427. PubMed ID: 29766239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases.
    Lahti SJ; Xing M; Zhang D; Lee JJ; Magnetta MJ; Kim HS
    J Vasc Interv Radiol; 2015 Aug; 26(8):1102-11. PubMed ID: 26210240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of yttrium-90 in the management of unresectable hepatocellular carcinoma and hepatic metastases.
    Kousik V; Promila P; Verma R; Gupta A
    Indian J Gastroenterol; 2016 May; 35(3):179-85. PubMed ID: 27185180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.
    Piduru SM; Schuster DM; Barron BJ; Dhanasekaran R; Lawson DH; Kim HS
    J Vasc Interv Radiol; 2012 Jul; 23(7):943-8. PubMed ID: 22609292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Radioembolization in Elderly (≥ 70 Years) and Younger Patients With Unresectable Liver-Dominant Colorectal Cancer.
    Kennedy AS; Ball DS; Cohen SJ; Cohn M; Coldwell D; Drooz A; Ehrenwald E; Kanani S; Rose SC; Nutting CW; Moeslein FM; Savin MA; Schirm S; Putnam SG; Sharma NK; Wang EA;
    Clin Colorectal Cancer; 2016 Jun; 15(2):141-151.e6. PubMed ID: 26541321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of yttrium-90 radioembolization for unresectable liver metastases of melanoma.
    Jia Z; Jiang G; Zhu C; Wang K; Li S; Qin X
    Eur J Radiol; 2017 Jul; 92():111-115. PubMed ID: 28624008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete eradication of hepatic metastasis from colorectal cancer by Yttrium-90 SIRT.
    Garrean S; Muhs A; Bui JT; Blend MJ; Owens C; Helton WS; Espat NJ
    World J Gastroenterol; 2007 Jun; 13(21):3016-9. PubMed ID: 17589957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-institution experience with selective internal radiation therapy (SIRT) for the treatment of unresectable colorectal liver metastases.
    O'Leary C; Greally M; McCaffrey J; Hughes P; Lawler LLP; O'Connell M; Geoghegan T; Farrelly C
    Ir J Med Sci; 2019 Feb; 188(1):43-53. PubMed ID: 29511912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: A systematic review.
    Jia Z; Wang W
    Eur J Radiol; 2018 Mar; 100():23-29. PubMed ID: 29496075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy.
    Sofocleous CT; Garcia AR; Pandit-Taskar N; Do KG; Brody LA; Petre EN; Capanu M; Longing AP; Chou JF; Carrasquillo JA; Kemeny NE
    Clin Colorectal Cancer; 2014 Mar; 13(1):27-36. PubMed ID: 24370352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yttrium-90 Hepatic Radioembolization for Advanced Chemorefractory Metastatic Colorectal Cancer: Survival Outcomes Based on Right- Versus Left-Sided Primary Tumor Location.
    Wu V; Li MD; Goodwin JS; Wehrenberg-Klee EP; Zurkiya O; Kalva SP; Ganguli S
    AJR Am J Roentgenol; 2021 Nov; 217(5):1141-1152. PubMed ID: 33594907
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
    Wang EA; Stein JP; Bellavia RJ; Broadwell SR
    Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors.
    Michl M; Haug AR; Jakobs TF; Paprottka P; Hoffmann RT; Bartenstein P; Boeck S; Haas M; Laubender RP; Heinemann V
    Oncology; 2014; 86(1):24-32. PubMed ID: 24401529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.
    Fendler WP; Philippe Tiega DB; Ilhan H; Paprottka PM; Heinemann V; Jakobs TF; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2013 Aug; 54(8):1202-8. PubMed ID: 23729697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.
    Kokabi N; Camacho JC; Xing M; El-Rayes BF; Spivey JR; Knechtle SJ; Kim HS
    Cancer; 2015 Jul; 121(13):2164-74. PubMed ID: 25847227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.